Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study.

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study.

Response to treatment of rheumatoid arthritis shows large inter-individual variability. This heterogeneity is observed with all the anti-rheumatic drugs, including the commonly used TNF inhibitors. It seems that drug-specific and target-specific factors lead individual patients to respond or not to...

Full description

Bibliographic Details
Main Authors:	Ignacio Ortea, Bernd Roschitzki, Rosario López-Rodríguez, Eva G Tomero, Juan G Ovalles, Javier López-Longo, Inmaculada de la Torre, Isidoro González-Alvaro, Juan J Gómez-Reino, Antonio González
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4822871?pdf=render

Similar Items

Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
by: Tatyana Valentinovna Mezenova, et al.
Published: (2012-04-01)

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
by: Joao Goncalves, et al.
Published: (2019-12-01)

Perineal pyoderma gangrenosum in a girl treated with adalimumab after infliximab failure Pioderma gangrenoso perineal en una niña tratado con adalimumab tras fallo a infliximab
by: Luisa Castro-Laria, et al.
Published: (2011-08-01)

Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis
by: Nicholas Beare, et al.
Published: (2023-06-01)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
by: Eun Soo Kim
Published: (2021-03-01)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
by: Assasi Nazila, et al.
Published: (2009-12-01)

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
by: Chen, Y, et al.
Published: (2006)

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
by: Chen, Y, et al.
Published: (2006)

Infliximab for the treatment of rheumatoid arthritis.
by: Blumenauer, B, et al.
Published: (2002)

Infliximab in the therapy of rheumatoid arthritis
by: G. V. Lukina, et al.
Published: (2016-05-01)

Adalimumab in the treatment of early rheumatoid arthritis
by: Y A Sigidin, et al.
Published: (2008-04-01)

Effect of Infliximab and Adalimumab on Experimental Colitis Following Orally Supplemented Iron
by: John Triantafillidis, et al.
Published: (2017-01-01)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
by: Song Christine H, et al.
Published: (2012-11-01)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
by: Henry Alistair I, et al.
Published: (2011-11-01)

Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
by: Carlos Henrique Marques dos Santos
Published: (2014-07-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
by: Arne Carlsen, et al.
Published: (2018-03-01)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis.
by: Monika Hebeisen, et al.
Published: (2019-01-01)

Long-term treatment of rheumatoid arthritis with adalimumab
by: Murdaca G, et al.
Published: (2013-05-01)

Infliximab in the treatment of rheumatoid arthritis
by: A Perdriger
Published: (2009-05-01)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
by: Roy M. Fleischmann, et al.
Published: (2018-08-01)

Infliximab and methotrexate in the treatment of rheumatoid arthritis
by: Lipsky, P, et al.
Published: (2000)

Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
by: Ayano Mori, et al.
Published: (2020-01-01)

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
by: M Rodgers, et al.
Published: (2011-02-01)

Use of Adalimumab in young patients with chronic uveitis in whom infliximab loses its efficacy
by: Giani TG, et al.
Published: (2008-09-01)

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation
by: C McLeod, et al.
Published: (2007-08-01)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
by: Taketo Suzuki, et al.
Published: (2019-02-01)

Uso de infliximabe em vasculite reumatóide Infliximabe use in rheumatoid vasculitis
by: Manoel Barros Bértolo
Published: (2007-08-01)

Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis
by: Muhammed B. Durak, et al.
Published: (2025-01-01)

Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
by: Sang Hyoung Park, et al.
Published: (2022-01-01)

Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis
by: Weishai Liu, et al.
Published: (2023-05-01)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
by: Beatriz Orts, et al.
Published: (2022-01-01)

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
by: K Malottki, et al.
Published: (2011-03-01)

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

PROSPECT IN TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS WITH ADALIMUMAB
by: E.I. Alexeeva, et al.
Published: (2008-12-01)

ADALIMUMAB: NEW OPPORTUNITIES OF RHEUMATOID ARTHRITIS TREATMENT
by: E.I. Alexeeva, et al.
Published: (2009-05-01)

ADALIMUMAB: NEW OPPORTUNITIES OF RHEUMATOID ARTHRITIS TREATMENT
by: E.I. Alexeeva, et al.
Published: (2009-01-01)

PROSPECT IN TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS WITH ADALIMUMAB
by: E.I. Alexeeva, et al.
Published: (2008-01-01)

Efficacy and tolerability of adalimumab (humira) in patients with active rheumatoid arthritis
by: I G Salikhov, et al.
Published: (2010-12-01)